NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION, 0.02%/0.005%

Side Effects & Adverse Event Reports


View Chart Data

18.7K

Adverse Events

46.9K

Side Effects

2011

Data Starting In

SymPedia Mobile App

Get our Mobile App for easy access to the latest reports on NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION, 0.02%/0.005%.

Understanding the potential Side Effects and Adverse Events of NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION, 0.02%/0.005% is essential for making informed health decisions. Our application provides in-depth reports based on real-world data, helping you explore how NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION, 0.02%/0.005% may affect your health.

View reports containing much more information including:

  • Age group - See how different age ranges experience side effects and adverse reactions.
  • Year - Track trends over time to understand changes in reported issues.
  • Biological sex - Compare how reports vary between men and women.
  • Weight - Examine the impact of body weight on side effects and adverse events.
Download Now

Frequently Asked Questions

Some questions about NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION, 0.02%/0.005% are asked frequently. We've answered the most frequent of those questions below

  • How many adverse events have been reported for NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION, 0.02%/0.005%?

    SymPedia shows NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION, 0.02%/0.005% adverse event reports for 18,651.

  • How many side effects have been reported for NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION, 0.02%/0.005%?

    SymPedia shows NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION, 0.02%/0.005% side effect reports for 46,894.

  • What year does the NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION, 0.02%/0.005% reporting data start?

    SymPedia reporting data on this page starts in 2011.

  • What years are included in the yearly chart for NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION, 0.02%/0.005%?

    SymPedia yearly chart data on this page covers 2011 to 2025.